Olaparib, Palbociclib and Fulvestrant for BRCA-Associated, ER/PR-Positive, Her2-Negative Metastatic Breast Cancer
Clinicaltrials.gov identifier:
NCT03685331
Study Contact Information:
Contact: Payal D. Shah, MD by phone: 855-216-0098
Alexandra Torres by phone: 855-216-0098
or Email: [email protected]
HOPE: Olaparib, Palbociclib and Fulvestrant for BRCA-Associated, ER/PR-Positive, Her2-Negative Metastatic Breast Cancer
About the Study
The goal of this study is to find the best dose and measure side effects of palbociclib when given together with and fulvestrant, in treating people with hormone receptor-positive (HR+), metastatic breast cancer who have a or mutation. Palbociclib and may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Fulvestrant is a type of treatment that may prevent breast cancer cell growth by blocking and progesterone receptor stimulation.
This study is no longer enrolling people.
This study is no longer enrolling people.
This study is no longer enrolling people.